Abbott Laboratories Q1 2026 Earnings Call Summary

Moby Intelligence

Thu, April 16, 2026 astatine 11:46 AM CDT 3 min read

• Performance successful the archetypal 4th aligned with interior expectations, characterized by the strategical completion of the Exact Sciences acquisition to found a high-growth beachhead successful crab diagnostics.

• Medical Device maturation of 8.5% was underpinned by double-digit show successful Electrophysiology, Heart Failure, and Rhythm Management, offsetting a weaker-than-expected respiratory investigating season.

• Nutrition results bespeak a deliberate modulation toward volume-driven maturation pursuing strategical pricing actions successful 2025, with aboriginal information indicating that measurement betterment is opening to travel these adjustments.

• The Core Lab Diagnostics concern is navigating a betterment signifier arsenic it laps important prior-year headwinds successful China related to volume-based procurement (VBP) and post-COVID dynamics.

• Management attributes the 7.5% maturation successful Diabetes Care to a impermanent planetary tender renewal hold and a hard year-over-year examination involving 2025 shelf-restocking cycles.

• Strategic positioning successful Electrophysiology was bolstered by the earlier-than-planned motorboat of 2 caller pulsed tract ablation (PFA) catheters, Volt and TactiFlex Duo.

• Full-year 2026 comparable income maturation is projected astatine 6.5% to 7.5%, assuming the full-year inclusion of Exact Sciences successful some existent and anterior periods.

• Management anticipates a maturation acceleration successful the 2nd fractional of the year, driven by the normalization of Nutrition volumes and the broadening of caller merchandise launches successful Electrophysiology.

• Guidance for the remainder of the twelvemonth adopts a blimpish stance connected respiratory testing, choosing not to forecast a compensatory beardown play successful Q4 pursuing the anemic Q1 results.

• The Exact Sciences acquisition is expected to lend astir $3 cardinal successful incremental income for 2026, though it introduces a $0.20 dilutive interaction to adjusted EPS owed to financing costs.

• Future maturation successful Diabetes Care is predicated connected upcoming catalysts, including imaginable CMS sum enlargement for benignant 2 non-insulin users and the motorboat of a dual-analyte glucose-ketone sensor.

• The acquisition of Exact Sciences closed connected March 23, 2026, starring to the adoption of 'comparable income growth' arsenic the superior metric to supply an apples-to-apples portfolio view.

• Financing costs related to the Exact Sciences transaction were absorbed earlier than primitively planned, impacting first-quarter adjusted net per share.

• Structural changes included moving the near atrial appendage (LAA) closure concern from Structural Heart to Electrophysiology to amended align with doc telephone points and accelerate adoption.

• Management noted that portion shipping lanes successful the Middle East person go constrained, determination has been nary worldly interaction connected request oregon reimbursement, with mitigation strategies focused connected localized inventory.